Understanding the causes of hypertrophic cardiomyopathy in children and adolescents
Official title: Mechanical and Metabolic Pathways Underlying MYBPC3 Hypertrophic Cardiomyopathy
Funded at University of Michigan at Ann Arbor · NIH-11110171 · Data updated 2026-11-12
This study is looking at how changes in a specific gene related to hypertrophic cardiomyopathy (HCM) affect the heart, using special lab models to better understand the disease in young people, with the hope of finding new treatments to help those with HCM live healthier lives.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | May 15, 2025 |
| Project end | April 30, 2030 |
| Funding year | 2025 |
| Award (this year) | $167,400 |
| NIH project number | 1K08HL179262-01 |
| Project ID | NIH-11110171 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children and adolescents diagnosed with hypertrophic cardiomyopathy, particularly those with MYBPC3 gene mutations.
✕Less likely to help
Patients with hypertrophic cardiomyopathy not related to MYBPC3 mutations or those with other unrelated cardiac conditions may not benefit from this research.
What this research studies
This research investigates the molecular mechanisms behind hypertrophic cardiomyopathy (HCM), particularly focusing on the MYBPC3 gene, which is often mutated in affected individuals. The principal investigator, Dr. Joshua Meisner, is developing innovative models using induced pluripotent stem cells and mice to mimic the disease as it occurs in young patients. By studying these models, the research aims to uncover how mechanical and energetic stresses contribute to the progression of HCM, which can lead to serious health issues like heart failure. The ultimate goal is to identify potential therapeutic approaches that could improve outcomes for affected patients.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve the health and quality of life for children and adolescents with hypertrophic cardiomyopathy.
How similar studies have gone: Previous research has shown promise in using stem cell models to study cardiac diseases, indicating that this approach could yield valuable insights into hypertrophic cardiomyopathy.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Meisner, Joshua K — University of Michigan at Ann Arbor
- Study coordinator: Meisner, Joshua K
Related research
Other NIH-funded projects on the same topics.
-
SGLT inhibitors for non-obstructive hypertrophic cardiomyopathy
A testing of a diabetes drug class (SGLT2 inhibitors) to help people with non-obstructive hypertrophic cardiomyopathy feel better and reduce heart-related problems.
-
Using big biobanks to understand rare gene changes in hypertrophic cardiomyopathy
A large study will look at genetic data and health information from many people to better understand how rare gene changes influence hypertrophic cardiomyopathy and its risks.
-
Understanding heart disease in hypertrophic cardiomyopathy through heart tissue and blood analysis
Researchers are studying people with hypertrophic cardiomyopathy to see how genes and signaling in heart tissue and blood relate to disease progression and risk of serious heart problems.
-
Myosin binding protein C variants and heart disease
A doctor-scientist at the University of Michigan is studying how certain genetic changes in a heart protein (MYBPC3) cause hypertrophic cardiomyopathy and whether fixing the protein or its interactions could help people with this condition.
-
MEK inhibitor for severe infantile heart failure in Noonan and related RASopathies
A 12-month, multi-site trial tests whether the medicine trametinib can help infants with life-threatening heart failure due to Noonan syndrome and related genetic conditions.
-
MEK inhibitor shows promise for serious infant heart disease in Noonan/RASopathies
A multi-site study tests whether the drug trametinib can help infants with severe heart muscle thickening caused by Noonan syndrome and related RASopathies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.